

Breadcrumb

Entity Print



Tobias Alexander
ADWP Chair
Germany

Major achievements

Large randomised controlled trials have demonstrated the superiority of hematopoietic stem cell transplantation over standard-of-care therapies in systemic sclerosis and multiple sclerosis, which are now considered standard indications (Greco R et al., *BMT* 2025) and endorsed by their respective international societies (Del Galdo et al., *Ann Rheum Dis.* 2024) and ECTRIMS (Muraro et al., *Nat Rev Neurol.*

2025). The EBMT Autoimmune Diseases Working Party (ADWP) has been central to development of these approaches. Currently, 4839 patients have been reported to the EBMT registry (Fig. 1).




Figure 1: Auto-HSCT cases reported to the EBMT Registry

Meanwhile, CAR-T cell therapies are emerging as therapeutic alternatives with curative potential. In this context, the ADWP was central in developing expert-based position statement and clinical practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee on **innovative cellular therapies for ADs** (Greco et al, *EClinicalMedicine.* 2024).

Recent achievements from our Working Party include a paper on **best practice recommendations for HSCT in rheumatologic indications** (Alexander T et al., BMT 2025). In addition, our WP was central in providing a **position paper for the use of HSCT in multiple sclerosis** (Muraro P et al., *Nat Rev Neurol* 2025) and we provided a **review on HSCT in aggressive multiple sclerosis** (Boffa G et al., Mult Scler 2025). Furthermore, a large retrospective analysis investigated the optimal conditioning regimen in MS (Greco R et al., BMT 2025), and we defined **relapse criteria in patients with systemic sclerosis treated with HSCT** (Del Papa N et al., BMT 2025).

The ADWP is dedicated to promoting clinical activities, teaching and translational research on HCT together with innovative cellular therapies as AD treatment. We continued to expand the evidence-base and support best-practice with studies and guidelines, including significant collaborative outputs with the EBMT Working Parties, JACIE, Trainee Committee, Patient Advocacy Committee and Nurses Group.
Education is key in the ADWP activities, including an educational meeting on “Advancements in cellular therapy for Autoimmune Diseases and Chronic Haematological Malignancies” held in Rome, and a harmonisation workshop on recommendations for CAR-T in rheumatic diseases that took place in Paris 2025.



Educational Meeting "Advancements in cellular therapy for Autoimmune Diseases and Chronic Haematological Malignancies"
18-20 September 2025, Rome, Italy

Principal research studies

CAR-T Cell Therapy in Autoimmune Diseases as Concomitant or Main Indication: a 2-step Joint Study on behalf of EBMT ADWP and CTIWP
Study type
Closed Survey/Study
Diseases
Auto immune disorders
Group
Autoimmune Diseases Working Party (ADWP)

Type of treatment
CAR T
Principal investigator
Raffaella Greco
Autoimmune and autoinflammatory complications after CAR-T cell therapy - a joint study on behalf of the EBMT - ADWP, CTIWP and TCWP
Study type
Retrospective Studies
Diseases
Acute Lymphatic Leukaemia (ALL)
Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)
Non-Hodgkin’s Lymphoma (NHL)
Group
GoCART Coalition
Autoimmune Diseases Working Party (ADWP)
Cellular Therapy & Immunobiology Working Party (CTIWP)
Complications Working Party (CWP)
Type of treatment
CAR T
Principal investigator
Matteo Doglio
Incidence and outcome of CMV and EBV reactivations after autologous HSCT for autoimmune diseases: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Study type
Retrospective Studies
Diseases
Auto immune disorders
Group
Autoimmune Diseases Working Party (ADWP)
Type of treatment

Principal investigator
Tobias Alexander
Outcomes of HSCT for autoimmune cytopenias (AIC): a Retrospective Registry Study from the Autoimmune Diseases Working Party (ADWP) and the Paediatric Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Study type
Retrospective Studies
Diseases
Auto immune disorders
Group
Autoimmune Diseases Working Party (ADWP)
Paediatric Diseases Working Party (PDWP)
Type of treatment

Principal investigator
Nichola Cooper
Observational Study in Multiple Sclerosis patients treated with autologous hematopoietic stem cell Transplantation (OMST)
Study type
Non-interventional Prospective Studies
Diseases
Auto immune disorders
Group
Autoimmune Diseases Working Party (ADWP)
Type of treatment
Autologous
Principal investigator
Riccardo Saccardi

Key publications

2025
BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party
Group
Autoimmune Diseases Working Party (ADWP)
1st listed author
Raffaella Greco
Journal
Bone Marrow Transplant.
2025

Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
Group
Autoimmune Diseases Working Party (ADWP)
Practice Harmonisation and Guidelines Committee
1st listed author
Tobias Alexander
Journal
Bone Marrow Transplant.
2025
Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
Group
Autoimmune Diseases Working Party (ADWP)
1st listed author
Giacomo Boffa
Journal
Mult Scler.
2025
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT
Group
Autoimmune Diseases Working Party (ADWP)
1st listed author
Paolo A Muraro
Journal
Nat Rev Neurol.
2025
Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation
Group
Autoimmune Diseases Working Party (ADWP)
1st listed author
Nicoletta Del Papa
Journal

Bone Marrow Transplant.

See the full list of the ADWP 2025 publications



Indicators


	2023	2024	2025
Impact factor	54.39	76.30	**63.80**
Oral presentations	16	8	**10**
Poster presentations	4	1	**2**
International educational events	3	2	**2**

Major educational events



Event

51st Annual Meeting of the EBMT



Event

Advancements in cellular therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Sep 18, 2025 - Sep 20, 2025 / Rome, Italy
Discover more

Webinars and e-courses

HSCT in Autoimmune Diseases E-Course
Panel Discussion: Autologous HSCT in Multiple Sclerosis
VISIT THE ADWP WEBPAGE